Most people with bladder cancer begin treatment by having surgery to remove their cancer. If bladder cancer has spread beyond your bladder, you might have chemotherapy first. This can help treat ...

Providing surgeons feedback and education on their performance significantly improved the quality of bladder cancer operations, finds a new clinical trial led by researchers at UCL, UCLH and the ...

Long-term outcomes of pembrolizumab (pembro) in combination with gemcitabine (gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial ...

Please provide your email address to receive an email when new articles are posted on . Transurethral resection of bladder tumor plus systemic therapy induced clinical complete response among a large ...

MILAN — Photodynamic diagnosis-guided transurethral resection of bladder tumors did not reduce recurrence rates of non–muscle-invasive bladder cancer (NMIBC) in the longer term compared with standard ...

Investigators observe no significant difference between the surgical approaches in 1-year progression rates. En bloc resection has the potential to improve outcomes in patients with non-muscle ...

“Identifying individuals at high risk for UTIs allows for more targeted treatment and care strategies, thereby enhancing patient safety.” — Yunlan Jiang, Chengdu University of Traditional Chinese ...

Toni Carlos, second from left, is enjoying an active life despite removal of her bladder in 2021 due to bladder cancer. In spring 2022, she celebrated her son Ryan’s high school graduation along with ...

UGN-102 had similar disease-free survival outcomes in non-muscle-invasive bladder cancer, regardless of whether the therapy was given with surgery. Groups of patients with newly diagnosed and ...

Patients with nonmuscle-invasive bladder cancer who received intravesical chemotherapy after transurethral resection of bladder tumor had a significantly lower 30-day complication rate compared with ...

UGN-102 shows a 79.6% complete response rate in recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer. UGN-102 offers a non-surgical alternative, avoiding cystoscopy and anesthesia, ...